White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
Members of Congress say that won’t work.
Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
After a “humble” start at NCI, von Eschenbach set unachievable goal.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- KRAS pioneer and Stephenson Prize winner Frank McCormick aims to prevent all KRAS cancers with a pill
- Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field









